Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

David Einhorn is Wrong on ‘iPrefs’: Apple Inc. (AAPL)

Page 1 of 2

GREENLIGHT CAPITALShareholder activist David Einhorn has made headlines in recent weeks arguing that Apple Inc. (NASDAQ:AAPL) can unlock shareholder value by issuing $236 billion in preferred shares. But this financial engineering doesn’t create any new wealth, and actually harms the company in the long-term. Apple shareholders should dismiss Einhorn’s ‘silly slideshow’ and ignore these types of financial shenanigans.

In theory…

Einhorn’s proposal is to create a new class of preferred stock that would be distributed to existing shareholders, paying a 4% dividend indefinitely. Einhorn believes this plan could unlock $150 billion in shareholder value.  But let’s put on our i-Banker suits and see how the proposal would work in theory.

The value of a business is determined by the company’s future cash flows discounted by an appropriate interest rate.

Here’s how Apple is roughly valued today.

The problem with Apple Inc. (NASDAQ:AAPL), in Einhorn’s view, is that the company is sub-optimally financed by expensive equity. Investors discount future cash flows at a high rate, reducing the value of the firm.

Preferreds are advantageous because they’re cheaper to issue than equity. Preferred shareholders will accept a lower return because yields are fixed and they’re first in line to receive any dividends.

By issuing $236 billion in preferreds, Apple Inc. (NASDAQ:AAPL) can reduce its cost of capital, lower the rate cash flows are discounted, and increase the value of the firm.

Amazing! Using the super computing power of a napkin, I’ve created $150 billion. Somebody call Harry Potter, because I just found the Philospher’s stone.

Page 1 of 2

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!